 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Efficacy of Bismuth-based Quadruple Therapy as First-line Treatment for Clarithromycin-resistant Helicobacter pylori Infection |
| Seung In Seo, Woon Geon Shin |
|
Korean J Helicobacter Up Gastrointest Res. 2022;22(3):243-245. Published online August 24, 2022 DOI: https://doi.org/10.7704/kjhugr.2022.0025 |
|
Efficacy of Bismuth-based Quadruple Therapy as First-line Treatment for Clarithromycin-resistant Helicobacter pylori Infection The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 2022;22(3):243-245  Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy Journal of Clinical Medicine. 2022;11(15):4440 The Efficacy of Two-Week Quadruple First-Line Therapy with Bismuth, Lansoprazole, Amoxicillin, Clarithromycin onHelicobacter pyloriEradication: A Prospective Study Helicobacter. 2013;18(6):454-458 Efficacy of two-week quadruple bismuth treatment versus levofloxacin concomitant Helicobacter Pylori infection regimen as empirical first-line therapy Syrian patients. A randomized controlled trial. . 2020; Bismuth‐containing quadruple therapy versus concomitant quadruple therapy as first‐line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross‐sectional, comparative, open trial Helicobacter. 2018;24(1): Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency Gut and Liver. 2022;16(6):807-808 Bismuth Containing Quadruple Therapy versus Tailored Therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area . 2019; Bismuth Containing Quadruple Therapy versus Tailored Therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area . 2019; Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study Helicobacter. 2023;28(3): Bismuth Containing Quadruple Therapy versus Tailored Therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area . 2019; |
